July 23 (Reuters) - BridgeBio Pharma Inc BBIO.O:
NOVEL HUMAN GENETICS EVIDENCE CONFIRMS ESTIMATES OF GENETIC PREVALENCE, UNDERDIAGNOSIS, AND POTENTIALLY GREATER SYMPTOM BURDEN OF GAIN-OF-FUNCTION CASR VARIANTS ASSOCIATED WITH ADH1
Source text: ID:nGNX1Kn4tx
Further company coverage: BBIO.O
((Reuters.Briefs@thomsonreuters.com;))